• 1. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 2. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 3. Dissolution of cork biopolymers in biocompatible ionic liquids
  Helga Garcia,Rui Ferreira,Marija Petkovic,Jamie L. Ferguson,Maria C. Leit?o,H. Q. Nimal Gunaratne,Luís Paulo N. Rebelo Green Chem., 2010,12, 367-369
• 4. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851
• 5. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552

Chemical Profile of 4-bromo-1-(2-fluoroethyl)-1H-pyrazole (CAS No. 1049730-35-9)

4-bromo-1-(2-fluoroethyl)-1H-pyrazole, identified by its Chemical Abstracts Service (CAS) number 1049730-35-9, is a fluorinated pyrazole derivative that has garnered significant attention in the field of pharmaceutical and agrochemical research. This compound belongs to the class of heterocyclic compounds, which are widely recognized for their diverse biological activities and potential applications in drug discovery. The structural features of this molecule, particularly the presence of both bromine and fluoroethyl substituents, make it a valuable scaffold for further chemical modifications and biological evaluations.

The pyrazole core is a six-membered aromatic ring containing two nitrogen atoms at positions 1 and 5. This structural motif is known for its stability and ability to interact with biological targets such as enzymes and receptors. The introduction of a bromine atom at the 4-position enhances the electrophilicity of the molecule, making it susceptible to nucleophilic substitution reactions, which are commonly employed in medicinal chemistry to introduce additional functional groups. The fluoroethyl group at the 1-position adds another layer of complexity, as fluorine atoms are known to influence metabolic stability, pharmacokinetic properties, and binding affinity.

In recent years, there has been a growing interest in fluorinated pyrazoles due to their demonstrated efficacy in various therapeutic areas. For instance, studies have shown that fluorinated pyrazoles exhibit anti-inflammatory, antiviral, and anticancer properties. The compound 4-bromo-1-(2-fluoroethyl)-1H-pyrazole has been investigated for its potential as a lead compound in the development of novel therapeutic agents. Its unique structural features make it an attractive candidate for further exploration in drug discovery pipelines.

One of the most compelling aspects of this compound is its potential as a kinase inhibitor. Kinases are enzymes that play a crucial role in cell signaling pathways and are often implicated in diseases such as cancer. By targeting specific kinases, it may be possible to develop treatments that modulate these pathways effectively. Preliminary studies have suggested that 4-bromo-1-(2-fluoroethyl)-1H-pyrazole can interact with certain kinase domains, leading to inhibition of their activity. This finding has opened up new avenues for research into kinase-dependent diseases.

Furthermore, the presence of both bromine and fluoroethyl substituents provides opportunities for further derivatization. For example, palladium-catalyzed cross-coupling reactions can be employed to introduce additional aryl or heteroaryl groups at various positions on the pyrazole ring. These modifications can be tailored to optimize binding affinity and selectivity against specific biological targets. Such structural diversification is a cornerstone of modern drug discovery efforts aimed at identifying compounds with improved pharmacological profiles.

The synthesis of 4-bromo-1-(2-fluoroethyl)-1H-pyrazole involves multi-step organic transformations that highlight the versatility of modern synthetic methodologies. Starting from commercially available precursors such as 2-fluoroethyl bromide and appropriately substituted pyrazoles, a series of reactions including nucleophilic substitution, elimination, and functional group interconversions can be employed to construct the desired structure. These synthetic strategies not only showcase the ingenuity of organic chemists but also provide valuable insights into the preparation of complex heterocyclic compounds.

In conclusion, 4-bromo-1-(2-fluoroethyl)-1H-pyrazole (CAS No. 1049730-35-9) represents a promising scaffold for pharmaceutical research due to its unique structural features and potential biological activities. Its investigation as a kinase inhibitor and its amenability to further chemical modifications make it an exciting compound for future studies. As research in fluorinated heterocycles continues to advance, compounds like this one will undoubtedly play a significant role in the development of next-generation therapeutics.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)